1. Home
  2. LIXT vs OBLG Comparison

LIXT vs OBLG Comparison

Compare LIXT & OBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • OBLG
  • Stock Information
  • Founded
  • LIXT 2005
  • OBLG 2000
  • Country
  • LIXT United States
  • OBLG United States
  • Employees
  • LIXT N/A
  • OBLG N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • OBLG Computer Software: Programming Data Processing
  • Sector
  • LIXT Health Care
  • OBLG Technology
  • Exchange
  • LIXT Nasdaq
  • OBLG Nasdaq
  • Market Cap
  • LIXT 4.1M
  • OBLG 4.4M
  • IPO Year
  • LIXT N/A
  • OBLG N/A
  • Fundamental
  • Price
  • LIXT $2.33
  • OBLG $3.60
  • Analyst Decision
  • LIXT
  • OBLG
  • Analyst Count
  • LIXT 0
  • OBLG 0
  • Target Price
  • LIXT N/A
  • OBLG N/A
  • AVG Volume (30 Days)
  • LIXT 18.9K
  • OBLG 34.7K
  • Earning Date
  • LIXT 11-12-2024
  • OBLG 11-07-2024
  • Dividend Yield
  • LIXT N/A
  • OBLG N/A
  • EPS Growth
  • LIXT N/A
  • OBLG N/A
  • EPS
  • LIXT N/A
  • OBLG N/A
  • Revenue
  • LIXT N/A
  • OBLG $2,759,000.00
  • Revenue This Year
  • LIXT N/A
  • OBLG N/A
  • Revenue Next Year
  • LIXT N/A
  • OBLG N/A
  • P/E Ratio
  • LIXT N/A
  • OBLG N/A
  • Revenue Growth
  • LIXT N/A
  • OBLG N/A
  • 52 Week Low
  • LIXT $1.31
  • OBLG $2.81
  • 52 Week High
  • LIXT $4.40
  • OBLG $14.80
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 54.46
  • OBLG 47.86
  • Support Level
  • LIXT $2.25
  • OBLG $3.33
  • Resistance Level
  • LIXT $2.68
  • OBLG $4.04
  • Average True Range (ATR)
  • LIXT 0.23
  • OBLG 0.33
  • MACD
  • LIXT 0.01
  • OBLG -0.04
  • Stochastic Oscillator
  • LIXT 53.90
  • OBLG 29.35

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About OBLG Oblong Inc.

Oblong Inc is a provider of patented multi-stream collaboration products and managed services for video collaboration and network solutions. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. Mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, real estate.

Share on Social Networks: